4,4'-Dithio-bis-benzolsulfonsaeure | 1161-11-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4,4'-Dithio-bis-benzolsulfonsaeure
• 英文别名: 4-[(4-Sulfophenyl)disulfanyl]benzenesulfonic acid
• CAS: 1161-11-1
• 化学式: C₁₂H₁₀O₆S₄
• 分子量: 378.472
• InChiKey: LUENVHHLGFLMFJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  176
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  4,4'-Dithio-bis-benzolsulfonsaeure 在 DL-半胱氨酸 作用下， 生成 4-巯基苯磺酸
  参考文献：
  名称：

  Rate constants and equilibrium constants for thiol-disulfide interchange reactions involving oxidized glutathione

  摘要：

  DOI：

  10.1021/ja00526a042
• 作为产物：
  描述：

  4-巯基苯磺酸 在 双氧水 、 sodium iodide 作用下， 以 乙腈 为溶剂， 以92.1 %的产率得到4,4'-Dithio-bis-benzolsulfonsaeure
  参考文献：
  名称：

  双(4-磺酸基苯基)二硫化物的制备方法

  摘要：

  本发明公开了合成式1所示化合物的新方法。该方法包括：利用式2所示化合物得到式3所示化合物；将式3所示化合物与式4化合物反应生成式5所示化合物；将式5所示化合物经反应生成式6所示化合物；和，将式6所示化合物经氧化生成式1所示化合物。本发明的方法安全、高收率、低成本且高效地制备双(4‑磺酸基苯基)二硫化物。

  公开号：

  CN115925597A
• 作为试剂：
  描述：

  DL-半胱氨酸 在 4,4'-Dithio-bis-benzolsulfonsaeure 作用下， 生成 DL-胱氨酸
  参考文献：
  名称：

  Rate constants and equilibrium constants for thiol-disulfide interchange reactions involving oxidized glutathione

  摘要：

  DOI：

  10.1021/ja00526a042

文献信息

• [EN] ACIDIC BATH FOR ELECTROLYTICALLY DEPOSITING A COPPER DEPOSIT CONTAINING HALOGENATED OR PSEUDOHALOGENATED MONOMERIC PHENAZINIUM COMPOUNDS<br/>[FR] BAIN ACIDE DE DEPOT ELECTROLYTIQUE D'UNE COUCHE DE CUIVRE CONTENANT DES COMPOSES DE PHENAZINIUM HALOGENES OU PSEUDOHALOGENES MONOMERIQUES
  申请人：ATOTECH DEUTSCHLAND GMBH

  公开号：WO2005049584A1

  公开（公告）日：2005-06-02

  For manufacturing particularly uniform and mirror bright copper coatings that are leveled and ductile as well using a relatively high current density, halogenated or pseudohalogenated monomeric pheanzinium compounds or a purity at least 85 mole-% and having the general chemical formula (I) are utilized in which R1, R2, R3, R4. R5, R6, R7, R7’’, R8, R9, X and A¯have the significations denoted in the claims. The compounds are prepared by diazotizing a suited starting compound prior to halogenating or pseudohalogenating it in the presence of mineral acid, diazotization means and halide or pseudohalide, with the reaction steps being run in one single vessel.

  为了制造特别均匀和镜面明亮的铜涂层，同时使用相对较高的电流密度，利用含有至少85摩尔％纯度并具有一般化学式（I）的卤代或假卤代单体苯并离子化合物，这些涂层具有平整和韧性，其中R1，R2，R3，R4，R5，R6，R7，R7’’，R8，R9，X和A¯具有所述权利要求所示的含义。在矿物酸，重氮化剂和卤化物或假卤化物的存在下，通过重氮化适当的起始化合物然后卤代或假卤代它来制备这些化合物，反应步骤在一个单一的容器中进行。
• Imidazoyl urea polymers and their use in metal or metal alloy plating bath compositions
  申请人：Atotech Deutschland GmbH

  公开号：US11066553B2

  公开（公告）日：2021-07-20

  The present invention relates to imidazoyl urea polymers and their use in aqueous acidic plating baths for metal or metal alloy deposition such as electrolytic deposition of copper or alloys thereof in the manufacture of printed circuit boards, IC substrates, semiconducting and glass devices for electronic applications. The plating bath according to the present invention comprises at least one source of metal ions and an imidazoyl urea polymer. The plating bath is particularly useful for filling recessed structures and build-up of pillar bump structures.

  本发明涉及咪唑基脲聚合物及其在水性酸性电镀浴中的应用，用于金属或金属合金沉积，例如在制造印刷电路板、集成电路基板、半导体和电子应用玻璃器件中的铜或其合金的电解沉积。根据本发明的电镀浴包括至少一种金属离子来源和一种咪唑基脲聚合物。该电镀浴特别适用于填充凹陷结构和构建柱形凸起结构。
• Mixture of oligomeric phenazinium compounds and acid bath for electrolytically depositing a copper deposit
  申请人：Brunner Heiko

  公开号：US20060226021A1

  公开（公告）日：2006-10-12

  For the reproducible manufacturing of particularly uniform and brilliant i.e., highly bright copper coatings that are leveled and ductile as well, a copper plating bath is utilized that contains as an additive a mixture of oligomeric phenazinium compounds. The mixture contains at least one phenazinium compound selected from the group comprising compounds containing two monomeric units and compounds containing three monomeric units having the general chemical formulae and set forth in the patent claims and in the specification as well as further oligomeric phenazinium compounds.

  为了实现制造特别均匀、亮度高且具有平整和可塑性的铜涂层，使用了含有寡聚苯并咪唑化合物混合物的铜电镀浴液作为添加剂。该混合物至少包含一种苯并咪唑化合物，所述化合物包括含有两个单体单元和含有三个单体单元的化合物，其具有在专利要求和说明书中所列出的化学式和，以及其他寡聚苯并咪唑化合物。
• [EN] HETEROCYCLIC COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSES HETEROCYCLIQUES ET PROCEDES D'UTILISATION
  申请人：NOVARTIS AG

  公开号：WO2003043985A1

  公开（公告）日：2003-05-30

  Compounds of the formula (I) provide pharmacological agents which are potent agonists of Peroxisome Proliferator-Activated Receptors (PPARs). Accordingly, the compounds of the instant invention are useful for the treatment of conditions mediated by the PPAR receptor activity in mammals. Such conditions include dyslipidemia, hyperlipidemia, hypercholesteremia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, hypertension, obesity, inflammation, arthritis, cancer, Alzheimer's disease, skin disorders, respiratory diseases, ophthalmic disorders, inflammatory bowel diseases, ulcerative colitis and Crohn's disease. The compounds of the present invention are particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X. Preferred are the compounds of the invention which are dual agonists of PPARa and PPARy receptors.

  式(I)的化合物是有效的过氧化物酶体增殖物激活受体（PPARs）激动剂，具有药理学作用。因此，本发明的化合物可用于治疗哺乳动物中由PPAR受体活性介导的疾病。这些疾病包括血脂异常、高脂血症、高胆固醇血症、动脉粥样硬化、高甘油三酯血症、心力衰竭、心肌梗死、血管疾病、心血管疾病、高血压、肥胖、炎症、关节炎、癌症、阿尔茨海默病、皮肤疾病、呼吸系统疾病、眼科疾病、炎症性肠病、溃疡性结肠炎和克罗恩病等。本发明的化合物特别适用于哺乳动物中作为降糖药物，用于治疗和预防因糖耐量受损、高血糖和胰岛素抵抗引起的疾病，如1型和2型糖尿病以及X综合征。本发明的化合物中，PPARa和PPARy受体的双重激动剂是首选的。
• Heterocyclic compounds and methods of use
  申请人：——

  公开号：US20040248936A1

  公开（公告）日：2004-12-09

  Compounds of the formula 1 provide pharmacological agents which are potent agonists of Peroxisome Proliferator-Activated Receptors (PPARs). Accordingly, the compounds of the instant invention are useful for the treatment of conditions mediated by the PPAR receptor activity in mammals. Such conditions include dyslipidemia, hyperlipidemia, hypercholesteremia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, hypertension, obesity, inflammation, arthritis, cancer, Alzheimer's disease, skin disorders, respiratory diseases, ophthalmic disorders, inflammatory bowel diseases, ulcerative colitis and Crohn's disease. The compounds of the present invention are particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X. Preferred are the compounds of the invention which are dual agonists of PPAR&agr; and PPAR&ggr; receptors.

  式1的化合物提供了具有强效 Peroxisome Proliferator-Activated Receptors（PPARs）激动剂作用的药理剂。因此，本发明的化合物对哺乳动物体内由 PPAR 受体活性介导的疾病的治疗具有用处。这些疾病包括：血脂异常、高脂血症、高胆固醇血症、动脉硬化、高三酰甘油血症、心力衰竭、心肌梗塞、血管疾病、心血管疾病、高血压、肥胖、炎症、关节炎、癌症、阿尔茨海默病、皮肤疾病、呼吸系统疾病、眼科疾病、炎症性肠病、溃疡性结肠炎和克罗恩病。本发明的化合物在哺乳动物体内特别有用，作为降血糖剂，用于治疗和预防与糖耐量受损、高血糖和胰岛素抵抗有关的疾病，如1型和2型糖尿病以及X综合征。本发明的优选化合物是 PPAR&agr; 和 PPAR&ggr; 双重激动剂。